Clinical analysis of two dosage regimens of paclitaxel plus carboplatin intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer

Abstract:

Objective：To explore short term curative effects and adverse reactions of two different dosage regimens of paclitaxel plus carboplatin intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer. Methods：Clinical data of 136 patients who were diagnosed as epithelial ovarian cancer and accepted chemotherapy in the department of obstetrics and gynecology in the Second Affiliated Hospital of Zhengzhou University from January 2011 to January 2013 were retrospectively analyzed. There were 62 cases in one day medication group and 74 cases in two days medication group. Short term curative effects and adverse reactions of chemotherapy in two groups were compared and analyzed. Results：There was no statistically significant difference in short term cura－tive effect between two therapeutic regimens for advanced epithelial ovarian cancer. There were statistically significant differences in distribution of bone marrow at all levels between two groups（P=0.000）. Distribution of nausea and vomiting at all levels were statisti－cally different between two groups（P=0.004）. There was no statistically significant difference in liver damage distribution at all levels between two groups（P=0.321）. There was no statistically significant difference in distribution of renal injury at all levels between two groups（P=0.086）. Distribution of abnormal nerve sensation at all levels was not statistically different between two groups（P=0.280）. Conclusions：Dosage regimen in two days medication group can replace paclitaxel plus carboplatin chemotherapy in the treat－ment of advanced epithelial ovarian cancer.